Document is current
Any future updates will be listed below
-
Authors
Hufnagel, Demetra H.
Wilson, Andrew J.
Saxon, Jamie
Blackwell, Timothy S.
Watkins, Jaclyn
Khabele, Dineo
Crispens, Marta A.
Yull, Fiona E.
Beeghly-Fadiel, Alicia http://orcid.org/0000-0001-9913-732X
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA214043)
National Institutes of Health (U54 CA163072)
Burroughs Wellcome Fund (1018894)
Mr. Chris Hill through Anglo-American Charity Ltd.
- License Information
-
More Information
Article History
Received: 18 May 2020
Accepted: 7 September 2020
First Online: 15 September 2020
Ethics approval and consent to participate
: Approval was previously obtained from the Vanderbilt University Medical Center (VUMC) Institutional Review Board for construction of a tissue microarray (TMA) and collection of clinical data for Gynecologic Oncology patients at VUMC from 1994 to 2004; as all patient data was de-identified and discarded tissue from routine clinical care was evaluated, we obtained a waiver of consent from the VUMC Institutional Review Board committee. Data collection and processing were performed in accordance with standard guidelines, including US Federal Policy for the Protection of Human Subjects and the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests. However, potential conflicts of interest may include the following: ABF reports reimbursement for committee service from the American College of Obstetricians and Gynecologists (ACOG); MAC reports grants and personal fees from Astra-Zeneca, grants from Tesaro, grants from Janssen Research and Development, grants from Leap Therapeutics, grants from Aprea Therapeutics, grants from Advaxis, and grants from Hoffman-LaRoche; and TSB reports grants from Boehringer Ingelheim and grants from Celgene.
